Sesen Bio, Inc. (SESN)
Stock Price:
$1.06 USD
0.02 (1.92%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
117.04M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-59.46M |
| Shares Out |
110.42M |
| EPS (ttm) |
-0.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$1.06 |
| Previous Close |
$1.04 |
| Change ($) |
0.02 |
| Change (%) |
1.92% |
| Day's Open |
1.09 |
| Day's Range |
1.02 - 1.09 |
| Day's Volume |
9,650,366 |
| 52-Week Range |
0.37 - 1.54 |
More Stats
| Market Cap |
117.04M |
| Enterprise Value |
74.56M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
110.42M |
| Float |
106.34M |
| EPS (basic) |
-0.82 |
| EPS (diluted) |
-0.68 |
| FCF / Share |
-0.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.73M |
| Short Ratio |
2.88 |
| Short % of Float |
1.40% |
| Beta |
1.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.98 |
| Revenue |
n/a |
| Operating Income |
-41.45M |
| Net Income |
-59.46M |
| Free Cash Flow |
-38.50M |
| Net Cash |
42.48M |
| Net Cash / Share |
0.38 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-24.66% |
| ROE |
-210.42% |
| ROIC |
1,306.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.42*
(222.64% upside)
Low
2.25
Current: $1.06
High
5.00
Target: 3.42
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | 0.43 | 29.98 | 0.99 | 2.24 | 1.33 | - | - |
| Revenue Growth | - | - | -98.58% | 2928.38% | -55.86% | 68.14% | - | - | - |
| Gross Profit | - | - | 0.43 | 29.98 | 0.99 | 2.24 | 1.33 | - | - |
| Operating Income | -36.87 | -25.70 | -20.16 | 1.77 | -35.20 | -32.93 | -16.48 | -19.48 | -12.68 |
| Net Income | -108 | -33.69 | -29.03 | 1.89 | -33.45 | -34.16 | -18.03 | -19.66 | -12.83 |
| Shares Outstanding | 90.93 | 61.77 | 26.11 | 21.08 | 18.99 | 14.64 | 1.35 | 0.99 | 0.80 |
| Earnings Per Share | -1.18 | -0.55 | -1.11 | 0.09 | -1.76 | -2.37 | -16.18 | -22.93 | -17.80 |
| Operating Cash Flow | -37.52 | -22.83 | -17.77 | 2.54 | -34.53 | -29.31 | -13.49 | -19.09 | -10.87 |
| Capital Expenditures | -0.14 | - | 0.10 | 0.33 | -0.29 | -0.14 | - | -0.11 | -0.81 |
| Free Cash Flow | -37.66 | -22.83 | -17.67 | 2.86 | -34.82 | -29.44 | -13.49 | -19.20 | -11.67 |
| Cash & Equivalents | 48.14 | 50.44 | 14.69 | 25.35 | 36.17 | 54.15 | 8.04 | 8.02 | 0.83 |
| Total Debt | - | - | - | - | 13.90 | 10.00 | 4.52 | 2.01 | 1.03 |
| Net Cash / Debt | 48.14 | 50.44 | 14.69 | 25.35 | 22.28 | 44.15 | 3.52 | 6.01 | -0.20 |
| Assets | 114 | 112 | 75.10 | 104 | 36.83 | 55.00 | 11.24 | 9.50 | 2.67 |
| Liabilities | 141 | 67.35 | 57.06 | 65.42 | 17.88 | 18.17 | 65.57 | 48.80 | 22.46 |
| Book Value | -26.70 | 44.21 | 18.03 | 38.68 | 18.94 | 36.83 | -54.33 | -39.30 | -19.79 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Sesen Bio, Inc. |
| Country |
United States |
| Employees |
25 |
| CEO |
Thomas R. Cannell |
Stock Information
| Ticker Symbol |
SESN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SESN |
| IPO Date |
February 6, 2014 |
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.